# Insilico Medicine Fact Sheet

Insilico Medicine, a leading and global clinical stage biotechnology company powered by generative AI, utilizing its proprietary Pharma.AI platform and cutting-edge automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico delivers innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain and obesity and metabolic disorders.

Among the AI-driven pipeline generated by Insilico Medicine, 10 in clinical development. The most advanced program, Rentosertib (formerly known as ISM001-055), is a potentially first-in-class drug candidate for the treatment of idiopathic pulmonary fibrosis. It has completed Phase 2a clinical trials and achieved promising positive results. We are also extending the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products, and veterinary medicine.

## Business Model

### Drug Discovery and Pipeline Development

Generates revenue through out-licensing drug candidates as well as co-development with other pharmaceutical companies utilizing Pharma.AI.

### Software Solutions

We grant our customers access to our Pharma.AI platform and collect subscription fees.

### Other Discovery Related to Non-pharma Sectors

Utilize Pharma.AI to discover novel molecules for specific topics related to non-pharma industry.

## Major BD deals

- **2026**  
  Upfront payment $115 million plus milestones  
  Total deal value near $2.75 billion, plus royalties

- **2021**  
  Upfront of $13 million + $15 million equity investment  
  Total deal value up to $82 million

- **2022**  
  Upfront plus target nomination fees of $21.5 million  
  Total deal value up to $1.2 billion, plus royalties

- **2023**  
  Upfront payment $80 million plus milestones  
  Total deal value close to $1 billion, plus royalties

- **2023**  
  Upfront payment $12 million plus milestones  
  Total deal value over $500 million, plus royalties

- **2024**  
  Upfront payment $20 million plus milestones  
  Total deal value over $550 million, plus royalties

- **2025**  
  Total deal value over $100 million, plus royalties

- **2025**  
  Total deal value over tens of millions of USD, plus royalties

- **2026**  
  Upfront and near-term R&D payments $32 million plus milestones  
  Total deal value over $888 million, plus royalties

### Hygtia Therapeutics

- **2026**  
  Upfront payment $10 million plus milestones  
  Total deal value $66 million

- **2026**  
  Total deal value near $120 million, plus royalties

- **2026**  
  Total deal value near $100 million plus royalties

- **2026**  
  Up to tens of millions of HKD per project in R&D support

## Pipeline Highlights

[Download PDF](https://tools.euroland.com/downloadpdf/evoMultiPage.aspx?url=/factsheet/HK-INSI_Redesign/factsheethtml.asp?Lang%3Denglish%26pdf%3D1)

## Contact

### Investor Relations

**Address:** 9F, Tower C, Chamtime Plaza, 2899 Jinke Road, Pudong New District, Shanghai  
**E-mail:** [ir@insilico.ai](mailto:ir@insilico.ai)